Abstract: Use of at least one fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A which is a antimicrobial peptide and/or at least one Cationic AntiMicrobial Peptide, polypeptide C for the preparation of a medicament for treating a cancer and/or a microbial infection wherein the medicament is suitable for oral administration pre food intake.

Abstract: A method of producing at least one specific pathogen free (SPF) non-human animal and/or a method of producing at least one specific pathogen resistant (SPR) non-human animal, the method comprising administration of a fusion protein to the surviving animal wherein the fusion protein comprises at least one polypeptide B which is a Type 1 Ribosome Inactivating Protein (RIP) or fragment thereof; and (i) at least one polypeptide A which is an Antimicrobial peptide; and/or (ii) at least one polypeptide C which is a Cationic Antimicrobial Peptide (CAP) or fragment thereof.